Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2Phase NA 1

Status

Completed 110Unknown 27Terminated 18Withdrawn 6Recruiting 3Active not recruiting 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 1CNS 1

Conditions

Recurrence 1Medulloblastoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Large Granular Lymphocytic 1Ependymoma 1

Interventions

pembrolizumab 219Carboplatin 218Specimen Handling 198Cisplatin 188Magnetic Resonance Spectroscopy 168Radiotherapy 152Bevacizumab 142Gemcitabine 135Cyclophosphamide 133Drug Therapy 118Capecitabine 118Paclitaxel 112Oxaliplatin 110Biopsy 107venetoclax 102Nivolumab 101Rituximab 83tislelizumab 81durvalumab 81toripalimab 77Fluorouracil 73Etoposide 72Dexamethasone 70sintilimab 67Radiosurgery 67Docetaxel 67Pemetrexed 65atezolizumab 64Azacitidine 63Injections 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Recruiting × Thalidomide × Clear all
NCT01356290 2026-02-23

MEMMAT

Medical University of Vienna

Phase 2 Recruiting
232 enrolled
CNS

Ependymoma, Medulloblastoma, Recurrence

NCT06530576 2025-11-18

Thalidomide for the Symptomatic Large Granular Lymphocytic Leukemia

Institute of Hematology & Blood Diseases Hospital, China

Phase 2 Recruiting
48 enrolled
Other hematologic neoplasm

Leukemia, Large Granular Lymphocytic

NCT03980002 2019-06-10

BDHCLL001

Institute of Hematology & Blood Diseases Hospital, China

Phase 2 Recruiting
50 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡